REVVITY, INC.

We are a leading provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

The principal products and services of our two reportable segments are:

•Life Sciences. Provides products and services targeted towards life sciences customers.

•Diagnostics. Develops diagnostics, tools and applications focused on clinically-oriented customers, especially within the areas of reproductive health and emerging market diagnostics.

Effective at the beginning of fiscal year 2025, we implemented changes to our operating model. The majority of our Applied Genomics business, previously reported as part of the Diagnostics segment, has been integrated into a newly formed Life Sciences Solutions business, encompassing all Life Sciences reagents and consumables, instruments and services, as well as technology and licensing, which is reported as part of the Life Sciences segment. Beginning in fiscal year 2025, the Life Sciences segment consists of Life Sciences Solutions and Software, while the Diagnostics segment consists of Immunodiagnostics and Reproductive Health.

Overview of the Second Quarter of Fiscal Year 2025

Our overall revenue in the second quarter of fiscal year 2025 was $720.3 million which increased by $28.6 million, or 4%, as compared to the second quarter of fiscal year 2024, reflecting an increase of $11.2 million, or 3%, in our Diagnostics segment revenue, and an increase of $17.4 million, or 5%, in our Life Sciences segment revenue. The increase in our Diagnostics segment revenue for the second quarter of fiscal year 2025 was driven by our Immunodiagnostics and Reproductive Health businesses. The increase in our Life Sciences segment revenue for the second quarter of fiscal year 2025 was driven by increased revenue in our Software business.

Our consolidated gross margins decreased 123 basis points in the second quarter of fiscal year 2025, as compared to the second quarter of fiscal year 2024, primarily due to increased tariffs and product mix shift partially offset by pricing actions. Our consolidated operating margins increased 20 basis points in the second quarter of fiscal year 2025, as compared to the second quarter of fiscal year 2024, primarily due to sales volume leverage and productivity gains offsetting gross margin headwinds.